Visualizing vesicular dopamine dynamics in Parkinson's disease.
It has been suggested that dopamine derived from exogenous levodopa may not follow vesicular dynamics in Parkinson's disease (PD). Using a novel PET method based on the sensitivity of [(11)C]-dihydrotetrabenazine (DTBZ) binding to changes in vesicular dopamine levels, we show here that striatal [(11)C]-DTBZ binding decreases after levodopa administration in advanced PD, likely reflecting an increase in vesicular dopamine levels. Endogenous dopamine and exogenously derived dopamine seem to follow the same vesicular dynamics.
de la Fuente-Fernández
Raúl
R
Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.
Sossi
Vesna
V
McCormick
Siobhan
S
Schulzer
Michael
M
Ruth
Thomas J
TJ
Stoessl
A Jon
AJ
D000978:Antiparkinson Agents / Q000627:therapeutic use; D001931:Brain Mapping; D002250:Carbon Radioisotopes; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017711:Nonlinear Dynamics; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D049268:Positron-Emission Tomography / Q000379:methods; D013747:Tetrabenazine / Q000031:analogs & derivatives
D000978:Antiparkinson Agents; D002250:Carbon Radioisotopes; C032811:dihydrotetrabenazine; D007980:Levodopa; D004298:Dopamine; D013747:Tetrabenazine